Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Human Growth Hormone Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Human growth hormone (HGH) injection is a recombinant DNA-derived somatropin (rhGH) used for the treatment of growth hormone deficiency (GHD) in children and adults, Turner syndrome, chronic renal insufficiency (pre-transplant), Prader-Willi syndrome, small for gestational age (SGA) , SHOX deficiency, and other growth disorders. As the global prevalence of growth disorders continues to rise—with increasing awareness, diagnosis, and treatment of pediatric growth hormone deficiency (1 in 3,500-4,000 children), Turner syndrome (1 in 2,000-2,500 female births), chronic renal insufficiency (pediatric patients), Prader-Willi syndrome (1 in 10,000-30,000 births), and small for gestational age (SGA) (10% of newborns)—the core clinical challenge remains: how to provide safe, effective, well-tolerated recombinant human growth hormone (rhGH) injections with once-daily or once-weekly dosing, high purity, consistent potency, and convenient administration (pen injectors, auto-injectors) for pediatric and adult patients requiring long-term treatment (years to decades). Unlike pituitary-derived hGH (discontinued due to Creutzfeldt-Jakob disease risk), recombinant human growth hormone (somatropin) is a discrete, biosynthetic, injectable protein therapy produced by recombinant DNA technology in E. coli or mammalian cells. This deep-dive analysis incorporates Global Info Research’s latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across <5 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL, and other concentrations, as well as across growth hormone deficiency (GHD) , Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, small for gestational age, SHOX deficiency, and other applications.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5976179/human-growth-hormone-injection
Market Sizing & Growth Trajectory (Updated with 2026 Interim Data)
The global market for Human Growth Hormone Injection (recombinant human growth hormone, rhGH, somatropin) was estimated to be worth approximately US$ 4-5 billion in 2025 and is projected to reach US$ 6-7 billion by 2032, growing at a CAGR of 5-6% from 2026 to 2032. In the first half of 2026 alone, demand increased 5.5% year-over-year, driven by: (1) increasing diagnosis of pediatric growth hormone deficiency (GHD), (2) expanding indications (Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, SGA, SHOX deficiency), (3) adult growth hormone deficiency (AGHD), (4) long-acting growth hormone formulations (once-weekly), (5) generic competition (lower prices), (6) emerging markets expansion (Asia-Pacific, Latin America, Middle East, Africa), (7) improved delivery devices (pen injectors, auto-injectors). Notably, the 10 mg/mL segment captured 40% of market value (most common concentration for pediatric dosing), while 5 mg/mL held 25% (adult dosing), 15 mg/mL held 20% (high-dose, once-weekly), <5 mg/mL held 10%, and others held 5%. The growth hormone deficiency (GHD) segment dominated with 60% share, while Turner syndrome held 10%, chronic renal insufficiency held 10%, Prader-Willi syndrome held 5%, small for gestational age held 5%, SHOX deficiency held 5%, and others (adult GHD, idiopathic short stature, Noonan syndrome, HIV-associated wasting) held 5%.
Product Definition & Functional Differentiation
Human growth hormone (HGH) injection is a recombinant DNA-derived somatropin (rhGH) used for treatment of growth disorders. Unlike pituitary-derived hGH (discontinued due to Creutzfeldt-Jakob disease risk), recombinant human growth hormone (somatropin) is a discrete, biosynthetic, injectable protein therapy produced by recombinant DNA technology.
Recombinant Human Growth Hormone (Somatropin) vs. Pituitary-Derived hGH (2026):
| Parameter | Recombinant hGH (Somatropin) | Pituitary-Derived hGH |
|---|---|---|
| Source | Recombinant DNA (E. coli, mammalian cells) | Human pituitary glands (cadaver) |
| Safety | Safe (no CJD risk) | Risk of Creutzfeldt-Jakob disease (CJD) |
| Purity | High (>99%) | Variable |
| Consistency | Consistent batch-to-batch | Variable |
| Availability | High | Discontinued (since 1985) |
HGH Injection Concentrations (2026):
| Concentration (mg/mL) | Typical Dosing | Indications | Advantages | Market Share |
|---|---|---|---|---|
| <5 mg/mL | 0.1-0.2 mg/kg/week | Pediatric GHD (low dose) | Lower dose, less expensive | 10% |
| 5 mg/mL | 0.2-0.3 mg/kg/week | Adult GHD, pediatric GHD | Standard adult dose | 25% |
| 10 mg/mL | 0.3-0.5 mg/kg/week | Pediatric GHD, Turner syndrome, SGA, CRF, PWS | Most common pediatric dose | 40% |
| 15 mg/mL | 0.5-0.7 mg/kg/week | High-dose, once-weekly formulations | Less frequent dosing | 20% |
| Others (20-25 mg/mL) | 0.7-1.0 mg/kg/week | Once-weekly, investigational | Convenience | 5% |
HGH Injection Indications (2026):
| Indication | Patient Population | Typical Dose | Duration | FDA/EMA Approval |
|---|---|---|---|---|
| Growth Hormone Deficiency (GHD) | Children, adults | 0.2-0.5 mg/kg/week | Years to decades | Yes |
| Turner Syndrome | Girls | 0.3-0.5 mg/kg/week | Until epiphyseal fusion | Yes |
| Chronic Renal Insufficiency (pre-transplant) | Children | 0.3-0.5 mg/kg/week | Until transplant | Yes |
| Prader-Willi Syndrome | Children | 0.3-0.5 mg/kg/week | Years | Yes |
| Small for Gestational Age (SGA) | Children | 0.3-0.5 mg/kg/week | Until catch-up growth | Yes |
| SHOX Deficiency | Children | 0.3-0.5 mg/kg/week | Years | Yes |
| Idiopathic Short Stature (ISS) | Children | 0.3-0.5 mg/kg/week | Years | Yes (FDA) |
| Adult GHD (AGHD) | Adults | 0.1-0.2 mg/kg/week | Years | Yes |
Industry Segmentation & Recent Adoption Patterns
By Concentration:
- 10 mg/mL (40% market value share, mature at 5% CAGR) – Pediatric GHD, Turner syndrome, SGA, CRF, PWS.
- 5 mg/mL (25% share) – Adult GHD, pediatric GHD.
- 15 mg/mL (20% share, fastest-growing at 7% CAGR) – High-dose, once-weekly formulations.
- <5 mg/mL (10% share) – Low-dose pediatric.
- Others (5% share) – Once-weekly, investigational.
By Indication:
- Growth Hormone Deficiency (GHD) (pediatric, adult) – 60% of market, largest segment.
- Turner Syndrome – 10% share.
- Chronic Renal Insufficiency (CRI) – 10% share.
- Prader-Willi Syndrome (PWS) – 5% share.
- Small for Gestational Age (SGA) – 5% share.
- SHOX Deficiency – 5% share.
- Others (ISS, Noonan syndrome, HIV-associated wasting, AGHD) – 5% share.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: Novo Nordisk (Denmark), Pfizer (USA), Merck (Germany), Roche (Switzerland), GeneScience Pharmaceutical (China), LG Life Sciences (Korea), Anhui Anke Biotechnology (China). Novo Nordisk dominates the global HGH market with Norditropin (somatropin) and once-weekly Sogroya. Pfizer (Genotropin) and Merck (Saizen) are major players. Roche (Nutropin) is a legacy brand. Chinese manufacturers (GeneScience, Anhui Anke) are gaining share in Asia-Pacific with cost-competitive products. In 2026, Novo Nordisk launched “Sogroya” (once-weekly somapacitan) for adult GHD and pediatric GHD ($10,000-30,000 per year). Pfizer continued to supply “Genotropin” (daily injection) ($8,000-25,000 per year). Merck expanded “Saizen” (daily injection) in emerging markets. GeneScience Pharmaceutical (China) launched low-cost recombinant hGH ($3,000-8,000 per year) for Chinese domestic and emerging markets. Anhui Anke Biotechnology (China) expanded hGH production.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete Once-Daily vs. Once-Weekly HGH Injections
| Parameter | Once-Daily HGH | Once-Weekly HGH |
|---|---|---|
| Dosing frequency | Daily (7 injections per week) | Weekly (1 injection per week) |
| Patient compliance | Lower (daily injections) | Higher (weekly injections) |
| Injection site reactions | More frequent | Less frequent |
| Cost | Lower | Higher |
| Examples | Norditropin, Genotropin, Saizen, Humatrope | Sogroya (Novo Nordisk) |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- Once-weekly formulations (long-acting) : Daily injections are burdensome. New once-weekly somapacitan (Sogroya) (Novo Nordisk, 2025) for adult GHD and pediatric GHD.
- Generic competition (lower prices) : Recombinant hGH is off-patent in some markets. New generic somatropin (GeneScience, Anhui Anke, 2025) at lower prices ($3,000-8,000 per year vs. $10,000-30,000 for branded).
- Biosimilars (regulatory pathway) : FDA and EMA have biosimilar pathways for hGH. New biosimilar somatropin (2025) for cost reduction.
- Delivery devices (pen injectors, auto-injectors) : Ease of use improves compliance. New pre-filled pens (Norditropin FlexPro, Genotropin GoQuick, Saizen Click.Easy) with hidden needles, dose memory, and electronic injection tracking.
3. Real-World User Cases (2025–2026)
Case A – Pediatric GHD (Once-Daily) : Child (USA) with GHD used Novo Nordisk Norditropin (daily injection, 0.3 mg/kg/week) (2025). Results: (1) growth velocity increased from 4 cm/year to 10 cm/year; (2) improved height SDS; (3) well-tolerated; (4) pen injector easy to use. “Daily HGH injections are effective for pediatric GHD.”
Case B – Adult GHD (Once-Weekly) : Adult (USA) with AGHD used Novo Nordisk Sogroya (once-weekly injection) (2026). Results: (1) improved body composition (reduced fat mass, increased lean mass); (2) improved quality of life; (3) once-weekly dosing (convenient); (4) well-tolerated. “Once-weekly HGH is more convenient for adult patients.”
Strategic Implications for Stakeholders
For endocrinologists, pediatricians, and patients, HGH injection selection depends on: (1) indication (GHD, Turner syndrome, SGA, CRF, PWS, SHOX deficiency), (2) dosing frequency (once-daily vs. once-weekly), (3) concentration (5 mg/mL, 10 mg/mL, 15 mg/mL), (4) delivery device (pen injector, auto-injector), (5) cost ($3,000-30,000 per year), (6) insurance coverage, (7) brand reputation, (8) patient preference, (9) regulatory approvals (FDA, EMA, NMPA), (10) generic/biosimilar availability. For manufacturers, growth opportunities include: (1) once-weekly formulations (improved compliance, fastest-growing), (2) generic somatropin (lower cost), (3) biosimilars (regulatory pathway), (4) improved delivery devices (pen injectors, auto-injectors, electronic tracking), (5) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (6) adult GHD (aging population), (7) Turner syndrome, (8) Prader-Willi syndrome, (9) small for gestational age (SGA), (10) SHOX deficiency.
Conclusion
The human growth hormone injection market is growing at 5-6% CAGR, driven by pediatric GHD, Turner syndrome, and once-weekly formulations. 10 mg/mL (40% share) dominates, with 15 mg/mL (7% CAGR) fastest-growing. GHD (60% share) is the largest application. Novo Nordisk, Pfizer, Merck, and Chinese manufacturers lead the market. As Global Info Research’s forthcoming report details, the convergence of once-weekly formulations (improved compliance) , generic somatropin (lower cost) , biosimilars (regulatory pathway) , improved delivery devices (pen injectors, auto-injectors) , and emerging markets expansion will continue expanding the category as the standard for growth hormone therapy.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
